DRUG Stock Analysis: Buy, Sell, or Hold?
DRUG - Bright Minds Biosciences Inc. Common Stock
$75.93
-1.91 (-2.45%)
▼
5d:
+13.92%
30d:
+23.34%
90d:
-9.12%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 13, 2026
30d
Get Alerted When DRUG Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called DRUG this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DRUG shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DRUG shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DRUG is currently trading at $75.93, which is considered extended relative to its 30-day fair value range of $61.21 to $71.92.
Technical Outlook: Technically, DRUG is in a downtrend. Immediate support is located at $63.44, while resistance sits at $78.85.
Market Sentiment: DRUG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $166.31 (+119.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DRUG is in a downtrend. Immediate support is located at $63.44, while resistance sits at $78.85.
Market Sentiment: DRUG has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $166.31 (+119.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$61.21 -
$71.92
Company Quality Score
57/100
(HOLD)
Options IV Signal
45th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BEARISH: Price extended above range (+5.6% above its trading range)
- NEUTRAL: Options fairly priced (IV 45th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 119.0% below Wall St target ($166.31)
Trading Range Analysis
30-Day Trading Range
$61.21 -
$71.92
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$8.25
(10.9%)
Support & Resistance Levels
Support Level
$63.44
Resistance Level
$78.85
Current Trend
Downtrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.28
Wall Street Target
$166.31
(+119.0%)
Share & Embed Analysis
Last updated: July 13, 2026 5:43 PM ET
Data refreshes hourly during market hours. Next update: 6:43 PM
Data refreshes hourly during market hours. Next update: 6:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRUG showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$441 | 60 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 67 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$32 | 61 BUY |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 59 HOLD |
